The Cardiovascular Domain’s mission is to apply discovery, translational science and excellence in clinical care, via single outward facing cohesive specialist  cardiac services, to improve life expectancy for patients with cardiovascular disease in Greater Manchester.

MAHSC represents one of the largest population catchments for tertiary cardiac services in Europe and offers a unique resource for clinical research.

This is also combined with training the next generation of healthcare staff and researchers to the highest standard. Through the strengths and catchment  populations of MAHSC partners, we will take early discovery and innovation from  basic underpinning research into practice, prove effectiveness, and disseminate  best practice across the MAHSC footprint.

The population within our partners suffer disproportionately from heart and  circulatory disease. Our services include two large tertiary cardiac units (Central  Manchester University Hospitals NHS Foundation Trust and University Hospital  of South Manchester) that together provide the highest quality specialist care to  a population of around 3.5 million people with additional provision of nationally  designated cardiopulmonary transplantation and ventricular assist services to  6.6 million people. Our partners also house major stroke and vascular surgery services.

In addition, the disease burden on the North West of England is particularly high for common diseases such as diabetes mellitus. We have successful research programmes that aim to improve the screening and treatment of this disease. We will:

(a)    Address the high amputation rates due to the highly variable provision of diabetes care (National Audit Office-May 2012) by combining national retinal screening with our pioneering technique of corneal confocal microscopy to quantify early neuropathy across Greater Manchester (Year 2) and establish a model which can be replicated nationally (2020).

(b)   Develop novel biomarkers and therapies for diabetic complications through the CADET facility. We will evaluate our candidate, Triethylenetetramine (TETA), which is approved by the FDA for Wilson’s disease, and has been identified as a new approach to treat copper-mediated oxidative stress and prevent or reverse the micro and macrovascular complications of diabetes.

The Cardiovascular Domain links basic science and transitional strength in The  University of Manchester Institute for Cardiovascular Sciences and Faculty of Life  Sciences, with cardiac and stroke care centres in the acute Trust partners, applied  research in the Greater Manchester Collaboration for Leadership in Applied  Health Research and Care (GM CLAHRC), and public health initiatives across  the City Region. The integration of these activities will enable us to improve the identification and management of cardiovascular risk, conduct translational research and enhance care delivery in Manchester and beyond.